KR102344344B1 - 허혈 환자의 진단 및 위험도 계층화를 위한 방법 및 키트 - Google Patents

허혈 환자의 진단 및 위험도 계층화를 위한 방법 및 키트 Download PDF

Info

Publication number
KR102344344B1
KR102344344B1 KR1020187032609A KR20187032609A KR102344344B1 KR 102344344 B1 KR102344344 B1 KR 102344344B1 KR 1020187032609 A KR1020187032609 A KR 1020187032609A KR 20187032609 A KR20187032609 A KR 20187032609A KR 102344344 B1 KR102344344 B1 KR 102344344B1
Authority
KR
South Korea
Prior art keywords
apo
glcnac
ischemia
kit
patient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020187032609A
Other languages
English (en)
Korean (ko)
Other versions
KR20190008216A (ko
Inventor
마에스트로 리나 바디몬
라폴스 주딧 쿠베도
캅마니 테레사 파드로
Original Assignee
푼다시오 인스티튜트 드 레세르카 드 로’스피딸 드 라 산타 크루 아이 상 파우
콘세호 수페리오르 데 인베스티가시오네스 시엔티피카스
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 푼다시오 인스티튜트 드 레세르카 드 로’스피딸 드 라 산타 크루 아이 상 파우, 콘세호 수페리오르 데 인베스티가시오네스 시엔티피카스 filed Critical 푼다시오 인스티튜트 드 레세르카 드 로’스피딸 드 라 산타 크루 아이 상 파우
Publication of KR20190008216A publication Critical patent/KR20190008216A/ko
Application granted granted Critical
Publication of KR102344344B1 publication Critical patent/KR102344344B1/ko
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/775—Apolipopeptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2400/00—Assays, e.g. immunoassays or enzyme assays, involving carbohydrates
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2440/00—Post-translational modifications [PTMs] in chemical analysis of biological material
    • G01N2440/38—Post-translational modifications [PTMs] in chemical analysis of biological material addition of carbohydrates, e.g. glycosylation, glycation
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2871—Cerebrovascular disorders, e.g. stroke, cerebral infarct, cerebral haemorrhage, transient ischemic event
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G01N2800/324—Coronary artery diseases, e.g. angina pectoris, myocardial infarction
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/56—Staging of a disease; Further complications associated with the disease

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
KR1020187032609A 2016-04-12 2017-04-12 허혈 환자의 진단 및 위험도 계층화를 위한 방법 및 키트 Expired - Fee Related KR102344344B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP16382167.1 2016-04-12
EP16382167.1A EP3232200A1 (en) 2016-04-12 2016-04-12 Methods and kits for the diagnosis and risk stratification of patients with ischemia
PCT/EP2017/058768 WO2017178521A1 (en) 2016-04-12 2017-04-12 Methods and kits for the diagnosis and risk stratification of patients with ischemia

Publications (2)

Publication Number Publication Date
KR20190008216A KR20190008216A (ko) 2019-01-23
KR102344344B1 true KR102344344B1 (ko) 2021-12-28

Family

ID=56008566

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020187032609A Expired - Fee Related KR102344344B1 (ko) 2016-04-12 2017-04-12 허혈 환자의 진단 및 위험도 계층화를 위한 방법 및 키트

Country Status (15)

Country Link
US (1) US11486884B2 (https=)
EP (2) EP3232200A1 (https=)
JP (1) JP7075894B2 (https=)
KR (1) KR102344344B1 (https=)
CN (1) CN109154620B (https=)
AU (1) AU2017251355A1 (https=)
BR (1) BR112018070971A2 (https=)
CA (1) CA3020666A1 (https=)
ES (1) ES2979390T3 (https=)
IL (1) IL262245B (https=)
MA (1) MA44658A (https=)
MX (1) MX2018012580A (https=)
RU (1) RU2750035C2 (https=)
SG (1) SG11201808820QA (https=)
WO (1) WO2017178521A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20230022141A (ko) 2021-08-06 2023-02-14 에이치앤비지노믹스 주식회사 지능형 오믹스 기반 개인별 맞춤형 복잡질환 발병 위험도 정보 제공 방법 및 장치

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3870614A1 (en) * 2018-10-23 2021-09-01 GlyCardial Diagnostics, S.L. Antibodies specific for glycosylated apoj and uses thereof
JP2022510403A (ja) * 2018-12-05 2022-01-26 グリカルディアル ダイアグノスティクス エセ． エレ． 虚血傷害および虚血再灌流傷害の予防および／または治療のための方法および組成物
KR102158726B1 (ko) 2019-04-17 2020-09-22 한림대학교 산학협력단 Itpr3 유전자 업스트림의 유전자간 영역을 포함하는 지연성 허혈 진단용 dna 메틸화 마커 조성물
KR102281657B1 (ko) 2019-12-23 2021-07-26 한림대학교 산학협력단 지연성 허혈 진단을 위한 cdhr5 유전자 과메틸화 마커
KR102281644B1 (ko) 2019-12-23 2021-07-23 한림대학교 산학협력단 지연성 허혈 진단을 위한 insr 유전자 과메틸화 마커
KR102312534B1 (ko) 2019-12-31 2021-10-13 한림대학교 산학협력단 뇌척수액 유래 미토콘드리아 마커를 이용한 지연성 허혈 진단 방법
KR102318236B1 (ko) 2020-02-18 2021-10-26 한림대학교 산학협력단 혈중 코펩틴의 농도를 이용한 지연성 뇌허혈 진단 방법
KR102336507B1 (ko) 2020-02-21 2021-12-06 한림대학교 산학협력단 국소뇌산소포화도를 이용한 지연성 뇌허혈 진단 방법
KR102369155B1 (ko) 2020-07-07 2022-02-28 한림대학교 산학협력단 근적외선 분광분석법을 이용한 지연성 뇌허혈 진단 방법
KR102473348B1 (ko) 2020-09-11 2022-12-05 한림대학교 산학협력단 지연성 뇌허혈 진단을 위한 kif3a 유전자 과메틸화 마커
KR102473349B1 (ko) 2020-09-11 2022-12-05 한림대학교 산학협력단 지연성 뇌허혈 진단을 위한 kifap3 유전자 과메틸화 마커
KR102473350B1 (ko) 2020-09-11 2022-12-05 한림대학교 산학협력단 지연성 뇌허혈 진단을 위한 racgap1 유전자 과메틸화 마커
KR102496589B1 (ko) 2020-09-11 2023-02-03 한림대학교 산학협력단 지연성 뇌허혈 진단을 위한 vhl 유전자 과메틸화 마커
KR102477501B1 (ko) 2020-09-15 2022-12-14 한림대학교 산학협력단 지연성 뇌허혈 진단을 위한 alb 유전자 저메틸화 마커
KR102477500B1 (ko) 2020-09-15 2022-12-14 한림대학교 산학협력단 지연성 뇌허혈 진단을 위한 oprm1 유전자 과메틸화 마커
KR102477502B1 (ko) 2020-09-15 2022-12-14 한림대학교 산학협력단 지연성 뇌허혈 진단을 위한 il5 유전자 저메틸화 마커
KR102398533B1 (ko) 2020-11-05 2022-05-13 한림대학교 산학협력단 지연성 뇌허혈 진단을 위한 뇌척수액 마이토파지 마커
KR102470789B1 (ko) 2020-11-05 2022-11-25 한림대학교 산학협력단 지연성 뇌허혈 진단을 위한 pink1 바이오마커
KR102466956B1 (ko) 2020-11-05 2022-11-11 한림대학교 산학협력단 지연성 뇌허혈 진단을 위한 dapk1 바이오마커
KR102398534B1 (ko) 2020-11-05 2022-05-13 한림대학교 산학협력단 지연성 뇌허혈 진단을 위한 bnip3l 바이오마커
CN113462744B (zh) * 2021-05-24 2023-06-23 中国药科大学 N-乙酰葡萄糖胺作为标志物在制备诊断缺血性脑中风试剂中的应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011098645A1 (es) 2010-02-09 2011-08-18 Consejo Superior De Investigaciones Científicas (Csic) Uso de las isoformas de apo j como biomarcadores de lesión tisular

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6140045A (en) 1995-03-10 2000-10-31 Meso Scale Technologies Multi-array, multi-specific electrochemiluminescence testing
AU8483698A (en) * 1997-07-15 1999-02-10 Bioprobes, Inc. Determining alcohol intake using sialic acid/apo j
US6197599B1 (en) 1998-07-30 2001-03-06 Guorong Chin Method to detect proteins
US20090166224A1 (en) * 2004-05-05 2009-07-02 Ziping Yang Multi-lectin affinity chromatography and uses thereof
EP2950098A1 (en) * 2009-07-14 2015-12-02 National Institute of Advanced Industrial Science and Technology Glycan markers as measure of disease state of hepatic diseases
EP2400304A1 (en) * 2010-06-22 2011-12-28 Centro de Investigación Cooperativa En Biomateriales ( CIC biomaGUNE) Method for the characterization of intermolecular interactions
JP2012107932A (ja) 2010-11-16 2012-06-07 Mitsubishi Chemicals Corp Ｃｌｕｓｔｅｒｉｎ蛋白質による脳梗塞の検査方法
CA2983828A1 (en) 2015-04-30 2016-11-03 Idexx Laboratories, Inc. Specific detection of clusterin isoforms
CN107957498A (zh) * 2016-10-18 2018-04-24 厦门德馨尚品医疗科技有限公司 一种含有载脂蛋白j的试剂盒及其在临床诊断中的应用

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011098645A1 (es) 2010-02-09 2011-08-18 Consejo Superior De Investigaciones Científicas (Csic) Uso de las isoformas de apo j como biomarcadores de lesión tisular

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
COMUNALE, MARY ANN et al., ‘Novel changes in glycosylation of serum Apo-J in patients with hepatocellular carcinoma’, Cancer Epidemiology and Prevention Biomarkers, 2011, Vol. 20, pp 1222-1229. 1부.*
CUBEDO, JUDIT et al., ‘Proteomic signature of Apolipoprotein J in the early phase of new-onset myocardial infarction’, Journal of Proteome Research, 2011, Vol. 10, pp 211-220. 1부.*

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20230022141A (ko) 2021-08-06 2023-02-14 에이치앤비지노믹스 주식회사 지능형 오믹스 기반 개인별 맞춤형 복잡질환 발병 위험도 정보 제공 방법 및 장치
KR102865129B1 (ko) 2021-08-06 2025-09-26 에이치앤비지노믹스 주식회사 지능형 오믹스 기반 개인별 맞춤형 복잡질환 발병 위험도 정보 제공 방법 및 장치

Also Published As

Publication number Publication date
MX2018012580A (es) 2019-02-25
US20190128900A1 (en) 2019-05-02
US11486884B2 (en) 2022-11-01
JP2019516966A (ja) 2019-06-20
RU2750035C2 (ru) 2021-06-21
WO2017178521A1 (en) 2017-10-19
EP3232200A1 (en) 2017-10-18
BR112018070971A2 (pt) 2019-01-29
IL262245B (en) 2021-03-25
EP3443353B1 (en) 2024-03-13
IL262245A (en) 2018-11-29
RU2018139780A3 (https=) 2020-07-24
JP7075894B2 (ja) 2022-05-26
RU2018139780A (ru) 2020-05-12
ES2979390T3 (es) 2024-09-25
MA44658A (fr) 2019-02-20
CN109154620A (zh) 2019-01-04
SG11201808820QA (en) 2018-11-29
AU2017251355A1 (en) 2018-11-08
KR20190008216A (ko) 2019-01-23
CN109154620B (zh) 2022-03-08
EP3443353A1 (en) 2019-02-20
CA3020666A1 (en) 2017-10-19

Similar Documents

Publication Publication Date Title
KR102344344B1 (ko) 허혈 환자의 진단 및 위험도 계층화를 위한 방법 및 키트
US9733261B2 (en) Methods and compositions for diagnosis and prognosis of stroke or other cerebral injury
CN109564225B (zh) 作为指示不良事件的标志物的组蛋白和/或proADM
EP3971570A2 (en) Galectin-3 immunoassay
CN108469523A (zh) 癌症的预后和诊断方法
KR20040039177A (ko) 국소빈혈을 위한 진단 마커
EP2630490B1 (en) Body fluid bin1 as a marker of cardiac health
EP2625202B1 (en) A new method for diagnosing hypertension as well as cardiomyopathies
Badimón Maestro et al. Methods and kits for the diagnosis and risk stratification of patients with ischemia
US20110045504A1 (en) Prognostic Prediction Method for Acute Coronary Syndrome
HK40003205A (en) Methods and kits for the diagnosis and risk stratification of patients with ischemia
HK40003205B (en) Methods and kits for the diagnosis and risk stratification of patients with ischemia
US20180224466A1 (en) Methods and compositions for diagnosis and prognosis of appendicitis and differentiation of causes of abdominal pain
EP2554995A1 (en) Troponin based rule in and rule out algorithm of myocardial infarction
HK40072995A (en) Galectin-3 immunoassay
EP2385372A1 (en) Kidney disease in normal and abnormal pregnancy
Dissayabutra et al. Increased protein excretion, including albumin, by children of patients with urolithiasis
JP2015017923A (ja) 糖尿病の病態進展を評価するためのバイオマーカー

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

D13-X000 Search requested

St.27 status event code: A-1-2-D10-D13-srh-X000

D14-X000 Search report completed

St.27 status event code: A-1-2-D10-D14-srh-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E601 Decision to refuse application
PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

X091 Application refused [patent]
AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PX0901 Re-examination

St.27 status event code: A-2-3-E10-E12-rex-PX0901

PX0701 Decision of registration after re-examination

St.27 status event code: A-3-4-F10-F13-rex-PX0701

X701 Decision to grant (after re-examination)
GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20241224

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

H13 Ip right lapsed

Free format text: ST27 STATUS EVENT CODE: N-4-6-H10-H13-OTH-PC1903 (AS PROVIDED BY THE NATIONAL OFFICE); TERMINATION CATEGORY : DEFAULT_OF_REGISTRATION_FEE

Effective date: 20241224

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20241224